Treatment of Locally Advanced Non–Small Cell Lung Cancer

Hematology/Oncology Clinics of North America

Volumn 31, Issue 1, 2017, Pages 45-57

  Tam, Kit ^a   Daly, Megan ^a   Kelly, Karen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoradiation; Locally advanced disease; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEFITINIB; LOMUSTINE; PACLITAXEL; PEMETREXED; PLACEBO; TECEMOTIDE; VINBLASTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMORADIOTHERAPY; CHRONIC LUNG FIBROSIS; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSOLIDATION SYSTEMIC THERAPY; COUGHING; DOSIMETRY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ESOPHAGITIS; ESOPHAGUS STENOSIS; EVENT FREE SURVIVAL; FORCED EXPIRATORY VOLUME; HUMAN; INDUCTION SYSTEMIC THERAPY; LOBECTOMY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG RESECTION; MAINTENANCE SYSTEMIC THERAPY; MEDICAL DECISION MAKING; MEDICAL HISTORY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INDUCED MYELOPATHY; RADIATION INJURY; REVIEW; SPIROMETRY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TIME TO TREATMENT; TREATMENT PLANNING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PROCEDURES; RADIOTHERAPY DOSAGE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; PACLITAXEL; RADIOTHERAPY DOSAGE;

EID: 84998879861     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2016.08.009     Document Type: Review

References (48)

1. 1 Goldstraw, P., Chansky, K., Crowley, J., et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:1 (2016), 39–51.
2. 2 Pak, K., Park, S., Cheon, G.J., et al. Update on nodal staging in non-small cell lung cancer with integrated positron emission tomography/computed tomography: a meta-analysis. Ann Nucl Med 29:5 (2015), 409–419.
3. 3 Brunelli, A., Kim, A.W., Berger, K.I., et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:5 Suppl (2013), e166S–e190S.
4. 4 Albain, K.S., Swann, R.S., Rusch, V.W., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:9687 (2009), 379–386.
5. 5 Andre, F., Grunenwald, D., Pignon, J.P., et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18:16 (2000), 2981–2989.
6. 6 Decaluwe, H., De Leyn, P., Vansteenkiste, J., et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 36:3 (2009), 433–439.
7. 7 Suntharalingam, M., Paulus, R., Edelman, M.J., et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 84:2 (2012), 456–463.
8. 8 Pless, M., Stupp, R., Ris, H.B., et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 386:9998 (2015), 1049–1056.
9. 9 Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 352:9124 (1998), 257–263.
10. 10 Lally, B.E., Detterbeck, F.C., Geiger, A.M., et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the surveillance, epidemiology, and end results database. Cancer 110:4 (2007), 911–917.
11. 11 Corso, C.D., Rutter, C.E., Wilson, L.D., et al. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. J Thorac Oncol 10:1 (2015), 148–155.
12. 12 Perez, C.A., Pajak, T.F., Rubin, P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59:11 (1987), 1874–1881.
13. 13 Dillman, R.O., Seagren, S.L., Propert, K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:14 (1990), 940–945.
14. 14 Sause, W., Kolesar, P., Taylor, S. IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:2 (2000), 358–364.
15. 15 Furuse, K., Fukuoka, M., Kawahara, M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:9 (1999), 2692–2699.
16. 16 Fournel, P., Robinet, G., Thomas, P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23:25 (2005), 5910–5917.
17. 17 Le Chevalier, T., Arriagada, R., Quoix, E., Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 10:Suppl 1 (1994), S239–S244.
18. 18 Zatloukal, P., Petruzelka, L., Zemanova, M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46:1 (2004), 87–98.
19. 19 Curran, W.J. Jr., Paulus, R., Langer, C.J., et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103:19 (2011), 1452–1460.
20. 20 Auperin, A., Le Péchoux, C., Rolland, E., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:13 (2010), 2181–2190.
21. 21 Friess, G.G., Baikadi, M., Harvey, W.H., Concurrent cisplatin and etoposide with radiotherapy in locally advanced non-small cell lung cancer. Cancer Treat Rep 71:7–8 (1987), 681–684.
22. 22 McCracken, J.D., Janaki, L.M., Crowley, J.J., et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol 8:5 (1990), 892–898.
23. 23 Yamamoto, N., Nakagawa, K., Nishimura, Y., et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28:23 (2010), 3739–3745.
24. 24 Belani, C.P., Choy, H., Bonomi, P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:25 (2005), 5883–5891.
25. 25 Vokes, E.E., Perry, M.C., Kindler, H.L., et al. The cancer and leukemia group B respiratory committee. Clin Cancer Res 12:11 Pt 2 (2006), 3581s–3588s.
26. 26 Senan, S., Brade, A., Wang, L.H., et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34:9 (2016), 953–962.
27. 27 Vokes, E.E., Herndon, J.E. 2nd, Kelley, M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:13 (2007), 1698–1704.
28. 28 Gandara, D.R., Chansky, K., Albain, K.S., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:10 (2003), 2004–2010.
29. 29 Hanna, N., Neubauer, M., Yiannoutsos, C., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:35 (2008), 5755–5760.
30. 30 Kelly, K., Chansky, K., Gaspar, L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:15 (2008), 2450–2456.
31. 31 Butts, C., Socinski, M.A., Mitchell, P.L., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15:1 (2014), 59–68.
32. 32 Cox, J.D., Azarnia, N., Byhardt, R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:9 (1990), 1543–1555.
33. 33 Bradley, J.D., Moughan, J., Graham, M.V., et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 77:2 (2010), 367–372.
34. 34 Blumenschein, G.R. Jr., Paulus, R., Curran, W.J., et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 29:17 (2011), 2312–2318.
35. 35 Bradley, J.D., Paulus, R., Komaki, R., et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:2 (2015), 187–199.
36. 36 Fernandes, A.T., Shen, J., Finlay, J., et al. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes. Radiother Oncol 95:2 (2010), 178–184.
37. 37 Sulman, E.P., Komaki, R., Klopp, A.H., et al. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol, 4, 2009, 5.
38. 38 Grills, I.S., Yan, D., Martinez, A.A., et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 57:3 (2003), 875–890.
39. 39 Ling, D.C., Hess, C.B., Chen, A.M., et al. Comparison of toxicity between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer 17:1 (2016), 18–23.
40. 40 Yom, S.S., Liao, Z., Liu, H.H., et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:1 (2007), 94–102.
41. 41 Movsas, B., Hu, C., Sloan, J., et al. Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial. JAMA Oncol 2:3 (2016), 359–367.
42. 42 Chen, A.B., Li, L., Cronin, A., et al. Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancer. J Thorac Oncol 9:12 (2014), 1788–1795.
43. 43 Harris, J.P., Murphy, J.D., Hanlon, A.L., et al. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88:4 (2014), 872–884.
44. 44 Shirvani, S.M., Jiang, J., Gomez, D.R., et al. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer 82:2 (2013), 252–259.
45. 45 Dang, J., Li, G., Ma, L., et al. Predictors of grade >/= 2 and grade >/= 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Acta Oncol 52:6 (2013), 1175–1180.
46. 46 Khalil, A.A., Hoffmann, L., Moeller, D.S., et al. New dose constraint reduces radiation-induced fatal pneumonitis in locally advanced non-small cell lung cancer patients treated with intensity-modulated radiotherapy. Acta Oncol 54:9 (2015), 1343–1349.
47. 47 Palma, D.A., Senan, S., Tsujino, K., et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85:2 (2013), 444–450.
48. 48 Drodge, C.S., Ghosh, S., Fairchild, A., Thoracic reirradiation for lung cancer: a literature review and practical guide. Ann Palliat Med 3:2 (2014), 75–91.